OpGen, Inc.

Last price update: 18 Jun 24 23:00 GMT

Previous close:
Day's range:
$2.47 - $2.55
Year's range:
$1.65 - $38.40
Net Income per Share:
Price-to-Earnings ratio:
52-week Price Range:
Average volume:

Company profile for OpGen, Inc.

OpGen, Inc. logo

OpGen, Inc. is a precision medicine company that is dedicated to developing and commercializing molecular microbiology solutions. The Company works to provide clinicians with the information they need to improve patient outcomes and reduce the spread of infections caused by multidrug-resistant microorganisms. OpGen’s product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic test for the detection and identification of bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies; and a Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kit. Additionally, the Company offers the ARES Technology Platform, which provides a reference database on antimicrobial resistance through next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and the Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers.

Since its incorporation in 2001, OpGen has grown to become a leader in developing advanced precision medicine solutions. The Company is continuously expanding its capabilities and working to make a real difference in the lives of patients. For example, in early 2020, OpGen partnered with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. This collaboration enables the Company to further increase its research and development activities. Moreover, OpGen regularly publishes research papers and journal articles in leading scientific journals such as Applied and Environmental Microbiology and the Journal of Clinical Microbiology. The Company is also investing in implementing the latest cutting-edge technology in its products, such as automated sample-to-answer analysis and artificial intelligence-powered bioinformatics solutions. In 2020, the Company was awarded a grant from the National Institute of Allergy and Infectious Diseases to further its research and development of a rapid diagnostics platform. Further, it was also named a Fierce Innovation Award finalist in the Medical Device category for its Unyvero technology. By helping clinicians to detect and identify infectious diseases quickly, OpGen is determined to improve patient outcomes, reduce healthcare costs, and make a significant impact on public health.

Stock exchanges:
Diagnostics & Research
240 813 1260
United States